消化器癌化学療法における口内炎に対するエレンタール（ed）の有用性の検討:― ed 併用群とed 非併用群との比較：後方視的検討―
中山 昇典,西村 賢,高木 精一,須江 聡一郎,浅見 昌樹,井口 靖弘,亀田 亮,井上 俊太郎,工藤 春菜,原田 大司,中園 綾乃,本橋 修 +11 more
- Vol. 47, Iss: 4, pp 105-110
Reads0
Chats0
About:
The article was published on 2013-01-01 and is currently open access. It has received 0 citations till now.read more
References
More filters
Journal ArticleDOI
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Christophe Tournigand,Thierry André,Emmanuel Achille,Gérard Lledo,Michel Flesh,Dominique Méry-Mignard,E. Quinaux,C. Couteau,Marc Buyse,Gérard Ganem,B. Landi,Philippe Colin,Christophe Louvet,Aimery de Gramont +13 more
TL;DR: Both sequences achieved a prolonged survival and similar efficacy in metastatic colorectal cancer and the toxicity profiles were different.
Journal ArticleDOI
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Wasaburo Koizumi,H. Narahara,Takuo Hara,Akinori Takagane,Toshikazu Akiya,Masakazu Takagi,Kosei Miyashita,Takashi Nishizaki,Osamu Kobayashi,Wataru Takiyama,Yasushi Toh,Takashi Nagaie,Seiichi Takagi,Yoshitaka Yamamura,Kimihiko Yanaoka,Hiroyuki Orita,Masahiro Takeuchi +16 more
TL;DR: S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer, and progression-free survival was significantly longer in patients assigned to S-1plus cis Platin than in those assigned to s-1 alone.
Journal ArticleDOI
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients
Stephen T. Sonis,Linda S. Elting,Dorothy M. K. Keefe,Douglas E. Peterson,Mark M. Schubert,Martin Hauer-Jensen,B. Nebiyou Bekele,Judith E. Raber-Durlacher,J. Peter Donnelly,Edward B. Rubenstein +9 more
TL;DR: An international multidisciplinary panel of experts assembled to create clinical practice guidelines for the prevention, evaluation, and treatment of mucositis.
Journal ArticleDOI
Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy
TL;DR: The authors attempted to determine the efficacy of oral glutamine in a randomized, double blind, crossover trial in cancer patients receiving chemotherapy, and found it to reduce oral mucositis in humans.
Journal ArticleDOI
Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial.
Eng-Yen Huang,Stephen Wan Leung,Chong-Jong Wang,Hui-Chun Chen,Li-Min Sun,Fu-Min Fang,Shyh-An Yeh,Hsuan-Chih Hsu,Ching-Yeh Hsiung +8 more
TL;DR: Oral glutamine may significantly reduce the duration and severity of objective oral mucositis during radiotherapy and may shorten the duration of > or = Grade 3 subjective mucositi.